Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000054.xml
Pharmacopsychiatry 2007; 40 - A096
DOI: 10.1055/s-2007-991771
DOI: 10.1055/s-2007-991771
Olanzapine versus placebo in adolescents with schizophrenia
Background: Antipsychotics are prescribed for adolescents with schizophrenia, yet they have not been approved nor systematically investigated in double-blind, placebo-controlled trials. Methods: Adolescents (13–17yrs) with schizophrenia received olanzapine (OLZ, 2.5–20mg/day) or placebo (PLC) in a 6-week double-blind, plac.-controlled trial. LOCF mean changes from baseline-to-endpoint were assessed on the BPRS-C, CGI-S, and PANSS scales. Response was defined as a >/=30% decrease in BPRS-C; CGI-S,
This study was supported by Eli Lilly & Co., Indianapolis, USA